Table 1

Study eligibility criteria

Characteristics	Details of what will be considered
Population	People with a new diagnosis of FIGO stage 3 and FIGO stage 4 endometrial cancer
Intervention	Neoadjuvant chemotherapy or radiotherapy prior to surgery
Comparator	Primary surgery followed by adjuvant chemotherapy or radiotherapy
Outcomes	Main outcomes of interest Overall survival Progression free survival Secondary outcomes Completeness of cytoreduction Patients who complete intended treatment Adverse events
Timing	Overall survival and progression free survival at 5 years will be compared Cytoreductive completeness at end of surgery will be compared Proportion of patients receiving both treatments within 6 months of initiation of treatment Adverse events up to 30 days of completing a treatment will be considered Long-term side effects of treatments persisting after first 6 months after treatment
Setting	Prospective and retrospective studies from any country will be considered